Roche has entered into an agreement with Nurix Therapeutics, reportedly worth $2.3 billion, to collaborate on a potential treatment. The partnership appears to focus on developing a BTK degrader, possibly called Bexobrutideg, for use in various fields including hematology, immunology, and neurology. The collaboration aims to co-develop and co-commercialize this potential treatment, which may be used to address blood cancer.